United States Chemotherapy-Induced Thrombocytopenia (CIT) Market Projected to Reach US$ 790 Million by 2031, Growing at a CAGR of 4.5% Driven by Rising Cancer Incidence and Advanced Thrombopoietin Therapies

Leander, Texas and Tokyo, Japan - Jan.09.2026, As per DataM intelligence research report "The Global Chemotherapy-Induced Thrombocytopenia Market reached US$ 1,393.34 million in 2024 and is expected to reach US$ 1,896.14 million by 2031, growing at a CAGR of 4.5% during the forecast period 2025-2031." Rising cancer incidence, increasing chemotherapy usage, and advancements in thrombopoietin receptor agonists are driving demand for effective CIT management therapies.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/chemotherapy-induced-thrombocytopenia-market?praneetha

☛ United States: Recent Industry Developments
✅ In December 2025, Positive topline data from ongoing Phase III trials for romiplostim (Amgen) in persistent CIT demonstrated improved platelet recovery and reduced need for dose delays in solid tumor patients, advancing toward potential regulatory submission.

✅ In November 2025, Clinical updates on avatrombopag (Sobi) highlighted its role in preventing severe thrombocytopenia in high risk chemotherapy regimens, with real world evidence supporting broader use in oncology settings.

✅ In October 2025, Interim results from the PROCLAIM trial for romiplostim showed promising efficacy in maintaining chemotherapy relative dose intensity for NSCLC, ovarian, and breast cancer patients with CIT.

☛ Japan: Recent Industry Developments
✅ In December 2025, Japanese oncology centers expanded use of approved thrombopoietic agents for CIT management, supported by national guidelines emphasizing platelet support in elderly cancer patients.

✅ In November 2025, Collaborations advanced real world studies on TPO-RAs in chemotherapy regimens common in Japan, focusing on solid tumors and improved treatment adherence.

✅ In October 2025, Local research progressed on biomarker driven approaches for predicting and managing CIT, integrating with precision oncology initiatives.

☛ Chemotherapy-Induced Thrombocytopenia Market: Drivers
The Chemotherapy-Induced Thrombocytopenia (CIT) market is growing due to escalating global cancer cases and intensive chemotherapy regimens that frequently cause low platelet counts, leading to bleeding risks, dose reductions, and treatment delays. Limited approved therapies outside specific regions highlight unmet needs, driving R&D in thrombopoietin receptor agonists (TPO-RAs) like romiplostim and avatrombopag for better platelet recovery.

Aging populations, higher solid tumor incidence, and focus on maintaining chemotherapy dose intensity support demand. Advancements in supportive oncology care, clinical trial progress, and awareness of CIT complications further accelerate adoption. Overall, the market is transforming CIT management to enable optimal cancer treatment with reduced morbidity.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chemotherapy-induced-thrombocytopenia-market?praneetha

☛ Chemotherapy-Induced Thrombocytopenia Market: Major Players
Swedish Orphan Biovitrum AB (Sobi), Amgen Inc., Novartis AG, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., Mylan N.V. (Viatris), Teva Pharmaceutical Industries Ltd., and others.

☛ Segment Covered in the Chemotherapy-Induced Thrombocytopenia Market :
By Drug Class :
Thrombopoietin Receptor Agonists lead the market with 48% share, driven by their ability to effectively stimulate platelet production, reduce bleeding risks, and support continuity of chemotherapy treatments. Thrombopoietic Agents hold 32% share, supported by increasing clinical adoption for patients with chemotherapy-induced low platelet counts and favorable safety profiles. Other drug classes capture 20% share, including emerging therapies and combination treatments currently under research or limited clinical use.

By End-User :
Hospitals dominate with 55% share, attributed to the high volume of chemotherapy treatments, specialized oncology departments, and need for in hospital monitoring of thrombocytopenia management. Specialty Clinics hold 30% share, growing due to outpatient oncology care centers offering targeted treatments and patient monitoring. Other end-users, including homecare providers and academic research centers, represent 15% share, catering to niche patient segments and clinical trials for novel thrombocytopenia therapies.

☛ Regional Analysis :
North America - 41.7%
North America leads with 41.7% share, driven by high cancer prevalence, advanced R&D, and robust clinical trials in the U.S.

Europe - 25%
Europe accounts for 25% share, supported by established healthcare systems and increasing supportive care adoption.

Asia Pacific - 25%
Asia Pacific holds 25% share and fastest growth, fueled by rising cancer burden, chemotherapy usage, and investments in Japan, China, and India.

Latin America - 5%
Latin America represents 5% share, with emerging awareness and access.

Middle East & Africa - 5% Share
Middle East & Africa account for 5% share, supported by healthcare expansions.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=chemotherapy-induced-thrombocytopenia-market?praneetha

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praneetha
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?praneetha

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.